Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease

Neurobiology of Disease

Rolando A.G. Garcia¹  Liansheng Liu²  Holly Burr²  M. Flint Beal²  Jason Gregorio³  Zhongyi Hu⁴  Susan E. Browne⁴  Reid W. von Borstel⁴  Alexis Gonzalez⁴  Denise Brenneman⁴  Jin Sheng⁴  Joel A. Saydoff⁴  Sylvain Cardin⁴ 

[1] Corresponding author. Fax: [phone].;Department of Neuroscience, Weill Medical College, New York, NY, USA;Discovery Research, Wellstat Therapeutics Corporation, Gaithersburg, MD 20878, USA;Neuroscience Research, Wellstat Therapeutics Corporation, 930 Clopper Road, Gaithersburg, MD 20878, USA;

关键词: Neuroprotective;    Pyrimidine;    Mitochondria;    Neurotrophin;    Free radicals;    Parkinson's disease;   

DOI  :  

来源: DOAJ

【 摘 要 】

Previously, uridine pro-drug 2′,3′,5′-tri-O-acetyluridine (PN401) was shown to be protective in the mitochondrial complex II inhibitor 3-nitropropionic acid model of Huntington's disease (HD). In this study, PN401 increased survival and improved motor function on the rotarod in both R6/2 and N171-82Q polyglutamine repeat mouse models of HD. PN401 significantly decreased neurodegeneration in both the piriform cortex and striatum although PN401 decreased huntingtin protein aggregates only in the striatum. Cortical and striatal brain-derived neurotrophic factor (BDNF) protein levels were reduced in the +/− compared to the −/− N171-82Q mice and PN401 treatment significantly increased cortical BDNF in both +/− and −/− mice, but PN401 did not affect striatal BDNF. These results suggest that PN401 may have beneficial effects in the treatment of neurodegenerative diseases such as HD.

【 授权许可】

Unknown